Business

Why Psychedelic Stocks Have Crashed in the Last 3 Months

Why Psychedelic Stocks Have Crashed in the Last 3 Months

Our resident psychedelic investor explains why psychedelic stocks are plummeting, and why patience can pay off big time.
You Can Now Buy Marley One Functional Mushrooms on Amazon

You Can Now Buy Marley One Functional Mushrooms on Amazon

Silo Wellness CEO Douglas K. Gordon tells Psychedelic Spotlight that this is a "crucial" step toward "the mainstream acceptance of psychedelics and overall de-stigmatization of mushrooms, by way of the functional category."
Psychedelic Business Spotlight: October 8, 2021

Psychedelic Business Spotlight: October 8, 2021

,
This week in psychedelic business news: Enveric Biosciences uses AI to identify viable psychedelic drug candidates; Novamind launches end-of-life palliative care program; and PharmaTher tests ketamine to treat Parkinson's Disease.

Interview with Bright Minds Biosciences’ CEO Ian McDonald

,
In today’s episode of the Psychedelic Spotlight podcast, the Psychedelic Investor, James Hallifax interviews Ian McDonald, CEO and Director of Bright Minds Biosciences. For any investors out there, you can find Bright Minds Biosciences trading…

Interview with James Lanthier, CEO of Mindset Pharma

,
In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.

Interview with Ian McDonald, CEO & Director of Bright Minds Biosciences

,
In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. We discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain. 

Meet Bright Minds: The NEXT GEN Psychedelics Company Tackling Pain, Depression and MORE (DRUG/BMBIF)

In today’s episode of the Psychedelic Spotlight Podcast, James Hallifax from the Psychedelic Investor YouTube Channel interviews Ian McDonald, CEO of Bright Minds BioScience. For any investors out there, Bright Minds ticker symbol is DRUG on the Canadian CSE and BMBIF on the American OTC market. In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. Bright Minds is a company working on second and third generation psychedelics to treat a variety of ailments including depression, PTSD, epilepsy, addiction and more. The driving philosophy is that while classic psychedelics such as psilocybin and LSD do show great potential to be used in a therapy setting to treat mental health issues, the compounds also have limitations. At Bright Minds, the goal is to engineer completely new compounds, often based on the structure of classical psychedelics, that keep the benefits of said drugs while doing away with potential negatives. Important to note is that while psychedelic derived drugs are a focus of the company, they also are creating non-psychedelic compounds for a variety of ailments, including different forms of addiction. In the interview we discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain. I had a blast in this interview, and I know you will find it fascinating! Enjoy! DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy Check out our Benziga discounts https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor Full Disclosure: This video is for entertainment only and shouldn't be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. The Psychedelic Investor has been hired for a period beginning on 28,09,2021 and ending on 29,09,2021 to publicly disseminate information about (BRIGHT MINDS BIOSCIENCE INC) via digital communications. We have been paid ($2000 CAD). #BrightMinds #ThePsychedelicInvestor #PsychedelicStocks
Psychedelic Business Spotlight: October 1, 2021

Psychedelic Business Spotlight: October 1, 2021

,
This week in psychedelic business news: more evidence supporting ketamine for depression; a new use for MDMA; Lobe Sciences makes a leap in treating PTSD; Delix raises big bucks; and BetterLife Pharma patents solution for cluster headaches.
Why NeonMind Is Betting on Psilocybin to Curb the Global Obesity Epidemic

Why NeonMind Is Betting on Psilocybin to Curb the Global Obesity Epidemic

The psychedelic bioscience company's top advisor tells Psychedelic Spotlight that psilocybin "affects at least the 5h2C receptor, which is dedicated towards appetite and appetite suppression."

© 2023 Psychedelic Spotlight. | Owned and operated by PSYC Media Corporation, Inc. a US publicly traded company (OTCPink: PSYC) | All Rights Reserved.